Stockwatch: The New Pharmaceutical Value Chain
This article was originally published in Scrip
After another week of significant share price volatility among life science stocks the bad news is that the bottom of this current bear market may not yet have been reached. And the worse news is that some significant changes to the pharmaceutical value chain became more apparent last week.
Register for our free email digests: